ArticleFrontiers in medicine2024
Real-world outcomes of Defocus Incorporated Multiple Segments lenses on retarding axial elongation in myopic children and adolescents.
Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Spectacle lenses for control of myopia progression in children.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Review
- Age Modifies the Comparative Effectiveness of DIMS Versus HAL Spectacle Lenses for Myopia Control: A Real-World Study.Translational vision science & technology · 2026Article
- Comparative Effectiveness of Myopia-control Spectacle Lenses: Clincial setting Performance from a Retrospective Cohort Study.Ophthalmology science · 2026Article
- The Role of Spectacle Lenses in the Control and Management of Myopia Progression: A Narrative Review.Life (Basel, Switzerland) · 2025Review
- Association between myopia progression and cylinder power progression in defocus incorporated multiple segments lens wearers.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to examine the effect of Defocus Incorporated Multiple Segments (DIMS) lenses on myopia progression and axial elongation in a clinical population. Methods: A retrospective study was conducted using clinical data from 489 and 156 patients aged 3 to 17 years old who were prescribed DIMS and single vision (SV) lenses, respectively at the Optometry Clinic of The Hong Kong Polytechnic University between July 2018 and August 2019. The study included patients with previous myopia control interventions. The changes in spherical equivalent refraction (SER) and axial length (AL) were measured and normalized to annual changes. The correlation between age at baseline and annual change in AL was also examined. Results: The total change in SER and AL after DIMS were -0.94 ± 0.79D and 0.55 ± 0.40 mm, respectively with an average wearing period of 31.98 ± 9.97 months. The normalized annual changes in SER and AL in DIMS wearers were significantly smaller than those in SV wearers (DIMS; SER change vs. AL changes; -0.38 ± 0.32D vs. 0.22 ± 0.16 mm. SV; -0.45 ± 0.41D vs. 0.29 ± 0.20 mm, Conclusion: The study demonstrated that DIMS lenses could retard axial elongation, with the effect sustained with increased duration of lens wear. However, patients with previous myopia control experienced greater myopia progression after wearing DIMS lenses. The study also highlighted the potential for axial length shortening in a small proportion of patients after the DIMS lens wear. These findings underscore the importance of adherence to intervention in achieving optimal treatment efficacy. Further research is needed to understand the mechanisms underlying these effects and to optimize the use of optical interventions in myopia control.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.